Be Ahead With Economy And Policy Updates
NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic
urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy.
Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep’25 as per industry sales data.
You are warmly welcomed to India’s first On-Demand News Platform. We are dedicated to fostering a democracy that encourage diverse opinions and are committed to publishing news for all segments of the society. If you believe certain issues or news stories are overlooked by mainstream media, please write to us. We will ensure your news is published on our platform. Your support would be greatly appreciated if you could provide any relevant facts, images, or videos related to your issue.
Newsletter
GAIL Appoints Manoj Kumar Sharma as Director (Projects)
PM Modi: Carbon Emissions Responsibility Wrongly Placed on Developing Countries
THDC India Wins ‘Green Future Leadership Award’
IREDA CMD Dr. Bijay Kumar Mohanty Emphasises Asset Quality and Good Governance Core to Growth
Maruti Suzuki Introduces Automatic S-CNG Swift, Dzire and Baleno
Hindustan Zinc adds 32 Mnt ore in FY26 as exploration success rate crosses 88%
